Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Don’t Expect Abandonment Of US FDA User Fee Programs If They Sunset
Jul 28 2022
•
By
Derrick Gingery
The prospect of a temporary lapse in authorization has stakeholders wondering what happens where the user fees end. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from User Fees
More from Pathways & Standards